FDAsafety guidance54% confidence
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma.
Regulatory Analysis
Application ANDA215411. Sponsor: INVENTIA HEALTHCARE LIMITED. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: SITAGLIPTIN, METFORMIN HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor and Biguanide
- Sub-indication
- General
Related signal: Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride